Targeted Oncology3d
Adjuvant T-DM1 Outperforms Trastuzumab in HER2-Positive Early Breast Cancer
Ado-trastuzumab emtansine led to improved overall survival and invasive disease–free survival over trastuzumab in patients ...
MedPage Today1mon
Survival Benefit With Adjuvant T-DM1 in High-Risk HER2-Positive Breast Cancer
Opens in a new tab or window Women with high-risk HER2-positive breast cancer lived significantly longer with adjuvant trastuzumab emtansine (T-DM1, Kadcyla), according to long-term follow-up of a ...
Targeted Oncology12d
T-DM1 Shows Tolerability in HER2+ Biliary Tract Adenocarcinoma
T-DM1 was tolerable in HER2-positive biliary tract adenocarcinoma but did not significantly improve progression-free survival ...
Medscape1mon
Trastuzumab Emtansine Ups Long-Term Survival in HER2-Positive Breast Cancer
Trastuzumab emtansine (T-DM1) demonstrates sustained improvement in invasive disease-free survival and reduced the risk for death in human epidermal growth factor receptor 2 (HER2)-positive breast ...
Nature1mon
Antibody–drug conjugates for cancer: poised to deliver?
Highlighted by Genentech's recent US regulatory submission for trastuzumab–DM1, antibody–drug conjugation technology could be heading for the mainstream in anticancer drug development.